A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic

  1. Ulrich Nübel3,25
  1. 1The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB19 1SA, United Kingdom;
  2. 2National University Health System, Singapore 119228;
  3. 3Robert Koch Institute, Wernigerode D-38855, Germany;
  4. 4Department of Infectious Disease Epidemiology, Imperial College London, St. Mary's Hospital Campus, London W2 1PG, United Kingdom;
  5. 5Laboratory of Molecular Genetics, Instituto de Tecnologia Química e Biológica (ITQB), Universidade Nova de Lisboa, 2784-505 Oeiras, Portugal;
  6. 6Laboratory of Microbiology, The Rockefeller University, New York, New York 10065, USA;
  7. 7Statens Serum Institut, DK-2300 Copenhagen, Denmark;
  8. 8Hvidovre Hospital, 2650 Hvidovre, Denmark;
  9. 9University of Copenhagen, Faculty of Health Sciences, DK-2200 Copenhagen, Denmark;
  10. 10National Institute of Public Health, Prague 10042, Czech Republic;
  11. 11Royal Perth Hospital, Perth WA 6000, Australia;
  12. 12Microbiology Services, Health Protection Agency, London NW9 5EQ, United Kingdom;
  13. 13Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, King's College London and Guy's and St. Thomas' NHS Foundation Trust, Greater London WC2R 2LS, United Kingdom;
  14. 14Aberdeen Royal Infirmary, Aberdeen City AB16, United Kingdom;
  15. 15University College London Hospital, London NW1 2BU, United Kingdom;
  16. 16Division of Infectious Diseases, Department of Medicine, Imperial College London, London W12 0NN, United Kingdom;
  17. 17Scottish MRSA Reference Laboratory, NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow G21 3UW, United Kingdom;
  18. 18The Roslin Institute and Edinburgh Infectious Diseases, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, United Kingdom;
  19. 19Microbiology, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, United Kingdom;
  20. 20Environmental Research Institute, University College Cork, Cork, Ireland;
  21. 21Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom
    • Present addresses: 22University of Cambridge, Cambridge CB2 1TN, United Kingdom;

    Abstract

    The widespread use of antibiotics in association with high-density clinical care has driven the emergence of drug-resistant bacteria that are adapted to thrive in hospitalized patients. Of particular concern are globally disseminated methicillin-resistant Staphylococcus aureus (MRSA) clones that cause outbreaks and epidemics associated with health care. The most rapidly spreading and tenacious health-care-associated clone in Europe currently is EMRSA-15, which was first detected in the UK in the early 1990s and subsequently spread throughout Europe and beyond. Using phylogenomic methods to analyze the genome sequences for 193 S. aureus isolates, we were able to show that the current pandemic population of EMRSA-15 descends from a health-care-associated MRSA epidemic that spread throughout England in the 1980s, which had itself previously emerged from a primarily community-associated methicillin-sensitive population. The emergence of fluoroquinolone resistance in this EMRSA-15 subclone in the English Midlands during the mid-1980s appears to have played a key role in triggering pandemic spread, and occurred shortly after the first clinical trials of this drug. Genome-based coalescence analysis estimated that the population of this subclone over the last 20 yr has grown four times faster than its progenitor. Using comparative genomic analysis we identified the molecular genetic basis of 99.8% of the antimicrobial resistance phenotypes of the isolates, highlighting the potential of pathogen genome sequencing as a diagnostic tool. We document the genetic changes associated with adaptation to the hospital environment and with increasing drug resistance over time, and how MRSA evolution likely has been influenced by country-specific drug use regimens.

    Footnotes

    • 23 University of Bath, Bath BA2 7AY, United Kingdom;

    • 24 University College London, Greater London WC1E 6BT, United Kingdom.

    • 25 Corresponding authors

      E-mail nuebelu{at}rki.de

      E-mail M.Achtman{at}ucc.ie

      E-mail mh3{at}sanger.ac.uk

    • [Supplemental material is available for this article.]

    • Article published online before print. Article, supplemental material, and publication date are at http://www.genome.org/cgi/doi/10.1101/gr.147710.112.

      Freely available online through the Genome Research Open Access option.

    • Received August 11, 2012.
    • Accepted January 7, 2013.

    This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported License), as described at http://creativecommons.org/licenses/by-nc/3.0/.

    | Table of Contents
    OPEN ACCESS ARTICLE

    Preprint Server